Company news

Corbus Pharmaceuticals Holdings, Inc. news in 2026

Corbus Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November

November 5, 2026

Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026

October 22, 2026

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

September 29, 2026

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

September 14, 2026

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

September 11, 2026

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

August 6, 2026

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

August 4, 2026

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

July 28, 2026

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

July 6, 2026

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

May 26, 2026

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

May 21, 2026

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

May 13, 2026

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

May 12, 2026

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

May 5, 2026

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

April 22, 2026

Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

April 13, 2026

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

April 6, 2026

Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit

March 18, 2026

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

March 8, 2026

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

February 12, 2026

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026